What is known and objective: Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor currently being investigated for the treatment of anemia in chronic kidney disease. Lanthanum carbonate is a phosphate binder that is commonly used to treat hyperphosphatemia in patients with chronic kidney disease. This study investigated the effect of lanthanum carbonate on the pharmacokinetics, safety and tolerability of a single oral dose of roxadustat in healthy non-elderly adult male subjects.
| WHAT IS K NOWN AND OBJEC TIVE
One of the functions of the kidneys is the synthesis of erythropoietin (EPO), a hormone that stimulates the production of red blood cells and maintains adequate levels of hemoglobin. In patients with chronic kidney disease (CKD), malfunction of the kidneys results in an insufficient rate of erythropoiesis due to decreased levels of EPO production. 1 Renal anaemia in patients with CKD becomes more prevalent as CKD progresses and is often associated with a reduced quality of life and work productivity, as well as an elevated risk for cardiovascular disease. family of transcription factors that up-regulate EPO production in response to hypoxia. 1 The ability of HIF-PHIs to increase blood EPO to levels close to the normal physiologic range, but lower than those induced by treatment with intravenous erythropoiesis-stimulating agents, may have the advantage of reduced adverse cardiovascular effects. 3 In addition, roxadustat has been shown to improve iron availability by reducing hepcidin, and may reduce the need for intravenous iron. [4] [5] [6] [7] Roxadustat reaches maximum plasma concentration within 2 hours of oral administration and is eliminated by phase I oxidation (cytochrome P450 2C8) and phase II conjugation (glucuronidation via uridine diphosphate-glucuronosyltransferase and glucosidation); the terminal elimination half-life (t ½ ) is approximately 12 hours in healthy subjects. 8 The solubility of roxadustat is pH dependent and absorption has been shown to be unaffected by food (data on file). Roxadustat is currently in Phase 3 trials for the treatment of anemia in patients with CKD, and has demonstrated safety and efficacy in Phase 2 studies in patients with CKD on dialysis 4, 6, 7 and not on dialysis. 5, 7 Hyperphosphatemia is a common complication of CKD that is associated with cardiovascular adverse effects and elevated all-cause and cardiovascular mortality. 9 Under normal conditions, the kidneys contribute to the maintenance of phosphate homeostasis via sodium-phosphate transporters that facilitate phosphate reabsorption, a process mediated by parathyroid hormone and fibroblast growth factor-23. As CKD progresses, this normal response is not sufficient for maintaining phosphate levels within a normal range, and hyperphosphatemia results. 9 The mainstay 
| ME THODS

| Study population
This study enrolled healthy male Japanese subjects aged 20-44 years, with a body weight of 50 to <80 kg and a body mass index of 17.6 to <26.4 kg/m 2 . Subjects had to agree to use two forms of highly effective birth control and to not donate sperm from the time of informed consent to ≥84 days after the last administration of roxadustat.
Subjects were excluded from the study if they received or were scheduled to receive any investigational drug within 120 days before screening, had donated blood (≥400 mL) within 90 days before screening, or received or were scheduled to receive medications or supplements within 7 days before admission to the hospital. Other key exclusion criteria included deviation from normal range of blood pressure, heart rate, body temperature, standard 12-lead electrocardiogram (ECG), and laboratory tests; concurrent or previous drug allergies; hepatic, heart, respiratory, renal, endocrine, or gastrointestinal disease; concurrent or previous malignant tumour; a history of abdominal surgery or digestive tract excision; concurrent or previous retinal neovascular lesions and macular edema; and previous use of HIF-PHIs.
| Study design
This was an open-label, randomized, two-period, twosequence crossover study (ClinicalTrials.gov; registration number: NCT02952040) in non-elderly healthy adult male subjects conducted at one contracted hospital in Japan. A crossover design was selected for this study to compare the PK of roxadustat in the presence and absence of lanthanum carbonate in an intra-subject manner. The duration of the washout period was selected to ensure full clearance of roxadustat.
Including PK and safety assessments and the ≥3-day washout, the total time between roxadustat doses was a minimum of 7 days, which is more than 10 times the t ½ (~12 hours) of roxadustat, as reported in a previous Phase 1 study. 8 The primary objective of this study was to evaluate the effect of 750 mg lanthanum carbonate TID (2250 mg/day) on the PK of a single oral dose of 100 mg roxadustat in non-elderly healthy adult male subjects. The secondary objective was to evaluate the safety of a single oral dose of 100 mg roxadustat administered concomitantly with lanthanum carbonate (750 mg, TID) in non-elderly healthy adult male Japanese subjects.
| Study drug administration
Roxadustat was provided as a single 100-mg tablet and was 
| Sample collection and assessments
Blood sampling for PK assessments was performed at pre-dose, and . The lower limit of quantification was 1.00 ng/mL, when using 0.05 mL of plasma. The intra-day precision (coefficient of variation) was 0.9%-4.4%, and the intra-day accuracy was 0.1%-10.7%. 
| Statistical methods
Statistical analysis was conducted using SAS ® Drug Development 
TA B L E 1 Subject demographics (safety analysis set)
were reported using summary statistics (number of observation [n], arithmetic mean, standard deviation, minimum, median, maximum, CV, geometric mean). To assess the impact of lanthanum carbonate on the PK of roxadustat, the natural log-transformed AUC inf and C max for roxadustat were analysed using a mixed effects analysis of variance model for treatment (roxadustat alone and roxadustat with lanthanum carbonate) with sequence and period as fixed effects and subject as a random effect. The GMR and corresponding 90% CI were calculated for AUC inf and C max .
| RE SULTS
| Subject disposition and demographics
Out of 45 subjects who provided informed consent, 18 were enrolled and randomized to Group 1 (n = 9) or Group 2 (n = 9); all subjects completed the study in accordance with the protocol and were included in the PK analysis set and safety analysis set. Data from one subject were excluded from the PK analysis due to two episodes of vomiting, 6.5 and 9.75 hours after administration of roxadustat 
| Pharmacokinetic analyses
Roxadustat was rapidly absorbed and the C max was reached within 1-4 hours when roxadustat was administered alone or concomitantly with lanthanum carbonate. The mean plasma concentrationtime profiles of roxadustat were similar to one another whether administered alone or concomitantly with lanthanum carbonate (Figure 1 ).
F I G U R E 1
Mean plasma concentration-time profile for roxadustat (PK analysis set) on a linear (A) and logarithmic (B) scale. Error bars represent standard deviation
The median t max of roxadustat was 2 hours when roxadustat was administered alone or concomitantly with lanthanum carbonate. The median t ½ of roxadustat was consistent whether administered alone (11.4 hours) or concomitantly with lanthanum carbonate (11.1 hours).
Of note, t ½ was not attained from one subject who received roxadustat alone and three subjects who received roxadustat concomitantly with lanthanum carbonate due to insufficient sampling points to adequately evaluate t ½ . Mean AUC inf and C max were 12% and 1.42% lower, respectively, when roxadustat was administered concomitantly with lanthanum carbonate compared with administration of roxadustat alone (Table 2) . However, the GMRs and 90% CIs for AUC inf and C max were both within the no-effect boundaries of 80% and 125%, indicating a lack of effect of lanthanum carbonate on roxadustat absorption (Table 2 ). The median (range) AUC % extrap for the whole population (roxadustat alone, n = 16; roxadustat + lanthanum carbonate, n = 15) was 0.6% (0.1%-7.6%).
| Safety
Throughout the study, one subject (5.6%) in the roxadustat alone group reported TEAEs of abdominal discomfort, nausea and vomiting that occurred on Day 1 after administration of roxadustat.
These events were mild or moderate in severity and were consid- 
| D ISCUSS I ON
The use of phosphate binders represents an important strategy to reduce phosphate absorption in the intestine. Given the potential for lanthanum carbonate and roxadustat to be administered concomitantly in patients with CKD and anemia in Japan, the primary objective of this study was to determine whether lanthanum carbonate affects roxadustat exposure in non-elderly healthy adult Japanese male subjects. Lanthanum carbonate has been shown in previous studies to decrease the AUC of oral ciprofloxacin 14 and levothyroxine 15 when administered concomitantly.
These drug-drug interactions may be due to formation of chelate complexes between lanthanum cations and concomitant drugs, resulting in reduced bioavailability. A similar drug-drug interaction study evaluated the pharmacokinetics of roxadustat when administered concomitantly with spherical carbon adsorbent and with or without food and reported that both conditions did not have a clinically relevant impact on the absorption of roxadustat. 17 Given that the potential interaction between roxadustat and lanthanum carbonate in this study would occur in the gastrointestinal tract and in turn impact the absorption of roxadustat, it TA B L E 2 Plasma pharmacokinetic parameters of roxadustat (PK analysis set) is not anticipated that any major differences in drug-drug interaction would be observed between healthy subjects and those with CKD. Overall, we found the AUC inf and C max of roxadustat to be 12% and 1.42% lower, respectively, when administered concomitantly with lanthanum carbonate; however, the GMRs for AUC inf and C max were 88.00% (90% CI: 84.01-92.17) and 98.58% (90% CI: 92.92-104.58), respectively, and the 90% CIs were within the no-effect boundaries of 80% and 125%. The median t max of roxadustat was 2 hours whether administered alone or concomitantly with lanthanum carbonate, and the median t ½ was also similar between the two groups (~11 hours). A median AUC % extrap of 0.6 indicated that the sampling was sufficient to provide an accurate estimate of the total AUC. However, due to the lack of sufficient sampling points, the t ½ could not be estimated for one subject in the roxadustat alone group and three subjects in the roxadustat plus lanthanum carbonate group. The ≥3-day washout period was selected to ensure full clearance of roxadustat between doses.
Even with the highest observed t ½ (24.6 hours), the minimum of 7 days between roxadustat doses allowed for ~7 half-lives between doses in this subject and ensured full clearance. There were no deaths, serious TEAEs or TEAEs resulting in discontinuation throughout this study. One subject (5.6%) treated with roxadustat alone reported TEAEs of abdominal discomfort, nausea and vomiting that were considered mild or moderate in severity, and possibly related to the administration of roxadustat.
| WHAT IS NE W AND CON CLUS I ON
Concomitant administration of a single oral dose of 100 mg roxadustat and 750 mg lanthanum carbonate TID for 2 days did not impact the AUC inf and C max of roxadustat in a clinically relevant manner, and was considered safe and well tolerated in non-elderly healthy adult male Japanese subjects. These results suggest that lanthanum carbonate may be safely administered concomitantly with roxadustat in CKD patients.
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